Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA9 | Q16790 | 2/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GFER | P55789 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30121548 | 1.00 | HCRTR2 (0.41) | HCRTR2TDP1MEN1KMT2AGAA | |
| SCHEMBL6672812 | 1.00 | HCRTR2 (0.41) | HCRTR2TDP1MEN1KMT2AGAA | |
| SCHEMBL23751101 | 0.91 | HCRTR2 (0.40) | HCRTR2TDP1MEN1KMT2AGAA | |
| SCHEMBL12070264 | 0.91 | HCRTR2 (0.43) | HCRTR2TDP1MEN1KMT2AGAA | |
| Hydrochloric Acid SCHEMBL22495697 | 0.89 | HCRTR2 (0.42) | HCRTR2TDP1MEN1KMT2AGAA | |
| SCHEMBL7392330 | 0.87 | HCRTR2 (0.45) | HCRTR2TDP1MEN1KMT2AGAA | |
| Hydrochloric Acid SCHEMBL30064967 | 0.86 | HCRTR2 (0.44) | HCRTR2TDP1MEN1KMT2AGAA | |
| SCHEMBL2277409 | 0.84 | TSHR (0.44) | KMT2AEPHX1TSHRSMYD3KDM4E | |
| SCHEMBL13641704 | 0.82 | HCRTR2 (0.48) | HCRTR2TDP1MEN1KMT2AGAA | |
| SCHEMBL23288607 | 0.82 | HCRTR2 (0.39) | HCRTR2TDP1MEN1KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250034150-A1 | BTK INHIBITORS | BIOGEN MA INC. | 2025-01-30 | — | — | US | disclosed |
| EP-4429770-A1 | BTK INHIBITORS | Biogen MA Inc. (US) | 2024-09-18 | — | — | EP | disclosed |
| US-20240293362-A1 | Soluble Epoxide Hydrolase Inhibitors and Use Thereof | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) | 2024-09-05 | — | — | US | disclosed |
| EP-3630770-B1 | PYRAZOLO[3,4-B]PYRAZINE DERIVATIVES AS SHP2 PHOSPHATASE INHIBITORS | RELAY THERAPEUTICS INC (US) | 2024-08-28 | — | — | EP | disclosed |
| WO-2023086521-A1 | BTK INHIBITORS | BIOGEN MA INC. (US) | 2023-05-19 | — | — | WO | disclosed |
| WO-2023086521-A1 | BTK INHIBITORS | BIOGEN MA INC. (US) | 2023-05-19 | — | — | WO | disclosed |
| WO-2023064370-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS AND USE THEREOF | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) | 2023-04-20 | — | — | WO | disclosed |
| US-11629145-B2 | SHP2 phosphatase inhibitors and methods of use thereof | D. E. SHAW RESEARCH, LLC (US) | 2023-04-18 | — | — | US | disclosed |
| US-11591336-B2 | Substituted pyrazolo[3,4-b]pyrazines as SHP2 phosphatase inhibitors | D. E. SHAW RESEARCH, LLC (US) | 2023-02-28 | — | — | US | disclosed |
| EP-3887370-B1 | TRICYCLIC COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTION | HOFFMANN LA ROCHE (CH) | 2023-01-18 | — | — | EP | disclosed |
| US-5585491-A | Antibacterial agents | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1996-12-17 | — | — | US | disclosed |
| US-5578604-A | BACTERICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1996-11-26 | — | — | US | disclosed |
| EP-0683169-A1 | 8-Amino-pyrido 1,2,3-de 1,3,4 benzoxadiazine derivatives, and antibacterial agents containing them | BAYER AG (DE) | 1995-11-22 | — | — | EP | disclosed |
| US-5468742-A | Antibacterial agents, feed additives | BAYER AKTIENGESELLSCHAFT (DE) | 1995-11-21 | — | — | US | disclosed |
| EP-0671391-A1 | 5-Vinyl- and 5-ethinyl-quinolinone- and -naphthyridone-carboxylic acids | BAYER AG (DE) | 1995-09-13 | — | — | EP | disclosed |
| EP-0523512-A1 | 8-vinyl- and 8-ethinyl-quinolone carboxylic acids | BAYER AG (DE) | 1993-01-20 | — | — | EP | disclosed |
| EP-0398967-A1 | ANTIBACTERIAL AGENTS | WARNER-LAMBERT COMPANY (US) | 1990-11-28 | — | — | EP | disclosed |
| US-4920120-A | 3-CARBOXY, 4-OXO, 6-FLUORO, 7-NITROGEN-CONTAINING RING 1,4-DIHYDRO-1,8-NAPHTHYRIDINES | WARNER-LAMBERT COMPANY (US) | 1990-04-24 | — | — | US | disclosed |
| EP-0326891-A2 | Antibacterial agents | WARNER-LAMBERT COMPANY (US) | 1989-08-09 | — | — | EP | disclosed |
| WO-1989006649-A2 | ANTIBACTERIAL AGENTS | WARNER-LAMBERT COMPANY (US) | 1989-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11629145-B2 | SHP2 phosphatase inhibitors and methods of use thereof | PTPRCAP, PTPRJ, PTPRC | HCRTR2 2742/4885TDP1 2149/4885MEN1 4412/4885 |
| US-11591336-B2 | Substituted pyrazolo[3,4-b]pyrazines as SHP2 phosphatase inhibitors | PTPN5, PTPN2, PTPN1 | HCRTR2 4116/4885TDP1 1939/4885MEN1 4220/4885 |
| US-20250034150-A1 | BTK INHIBITORS | BTK, SYK, LYN | HCRTR2 4706/4885TDP1 832/4885MEN1 2404/4885 |
| US-20240293362-A1 | Soluble Epoxide Hydrolase Inhibitors and Use Thereof | EPHX1, EPHX2, NCEH1 | HCRTR2 1293/4885TDP1 2152/4885MEN1 4563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.